273 related articles for article (PubMed ID: 19591808)
61. Use of biomarkers in the discovery of novel anti-schizophrenia drugs.
Mikkelsen JD; Thomsen MS; Hansen HH; Lichota J
Drug Discov Today; 2010 Feb; 15(3-4):137-41. PubMed ID: 20036755
[TBL] [Abstract][Full Text] [Related]
62. Adaptive evolution and elucidating the potential inhibitor against schizophrenia to target DAOA (G72) isoforms.
Sehgal SA; Mannan S; Kanwal S; Naveed I; Mir A
Drug Des Devel Ther; 2015; 9():3471-80. PubMed ID: 26170631
[TBL] [Abstract][Full Text] [Related]
63. Evidence for the interaction of D-amino acid oxidase with pLG72 in a glial cell line.
Sacchi S; Cappelletti P; Giovannardi S; Pollegioni L
Mol Cell Neurosci; 2011 Sep; 48(1):20-8. PubMed ID: 21679769
[TBL] [Abstract][Full Text] [Related]
64. D-serine and schizophrenia: an update.
Nunes EA; MacKenzie EM; Rossolatos D; Perez-Parada J; Baker GB; Dursun SM
Expert Rev Neurother; 2012 Jul; 12(7):801-12. PubMed ID: 22853788
[TBL] [Abstract][Full Text] [Related]
65. Human d-amino acid oxidase: The inactive G183R variant.
Murtas G; Caldinelli L; Cappelletti P; Sacchi S; Pollegioni L
Biochim Biophys Acta Proteins Proteom; 2018 Jul; 1866(7):822-830. PubMed ID: 29274788
[TBL] [Abstract][Full Text] [Related]
66. Expression of D-Amino Acid Oxidase (
Jagannath V; Marinova Z; Monoranu CM; Walitza S; Grünblatt E
Front Neuroanat; 2017; 11():31. PubMed ID: 28428746
[TBL] [Abstract][Full Text] [Related]
67. Characterization of human DAAO variants potentially related to an increased risk of schizophrenia.
Caldinelli L; Sacchi S; Molla G; Nardini M; Pollegioni L
Biochim Biophys Acta; 2013 Mar; 1832(3):400-10. PubMed ID: 23219954
[TBL] [Abstract][Full Text] [Related]
68. Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1).
Kapoor R; Lim KS; Cheng A; Garrick T; Kapoor V
Brain Res; 2006 Aug; 1106(1):205-210. PubMed ID: 16828464
[TBL] [Abstract][Full Text] [Related]
69. Optimization of D-amino acid oxidase for low substrate concentrations--towards a cancer enzyme therapy.
Rosini E; Pollegioni L; Ghisla S; Orru R; Molla G
FEBS J; 2009 Sep; 276(17):4921-32. PubMed ID: 19694805
[TBL] [Abstract][Full Text] [Related]
70. Controversial Effects of D-Amino Acid Oxidase Activator (DAOA)/G72 on D-Amino Acid Oxidase (DAO) Activity in Human Neuronal, Astrocyte and Kidney Cell Lines: The N-methyl D-aspartate (NMDA) Receptor Hypofunction Point of View.
Jagannath V; Brotzakis ZF; Parrinello M; Walitza S; Grünblatt E
Front Mol Neurosci; 2017; 10():342. PubMed ID: 29114206
[TBL] [Abstract][Full Text] [Related]
71. Structural, phylogenetic and docking studies of D-amino acid oxidase activator (DAOA), a candidate schizophrenia gene.
Sehgal SA; Khattak NA; Mir A
Theor Biol Med Model; 2013 Jan; 10():3. PubMed ID: 23286827
[TBL] [Abstract][Full Text] [Related]
72. [New pharmacological approaches to the treatment of schizophrenia].
Uzbay IT
Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
[TBL] [Abstract][Full Text] [Related]
73. Characterization of a yeast D-amino acid oxidase microbiosensor for D-serine detection in the central nervous system.
Pernot P; Mothet JP; Schuvailo O; Soldatkin A; Pollegioni L; Pilone M; Adeline MT; Cespuglio R; Marinesco S
Anal Chem; 2008 Mar; 80(5):1589-97. PubMed ID: 18229946
[TBL] [Abstract][Full Text] [Related]
74. Effect of ligand binding on human D-amino acid oxidase: implications for the development of new drugs for schizophrenia treatment.
Caldinelli L; Molla G; Bracci L; Lelli B; Pileri S; Cappelletti P; Sacchi S; Pollegioni L
Protein Sci; 2010 Aug; 19(8):1500-12. PubMed ID: 20521334
[TBL] [Abstract][Full Text] [Related]
75. [Neurotensine dipeptide analog dilept decreases the deficiency of prestimulus startle reflex inhibition: a prognostic sign of antipsychotic activity].
Ostrovskaia RU; Krupina NA; Gudasheva TA; Voronina TA; Seredenin SB
Eksp Klin Farmakol; 2009; 72(5):3-7. PubMed ID: 19928566
[TBL] [Abstract][Full Text] [Related]
76. [Pharmacogenetics of antipsychotics in schizophrenia].
Méary A
Therapie; 2008; 63(3):243-6. PubMed ID: 18718213
[TBL] [Abstract][Full Text] [Related]
77. D-amino-acid oxidase is involved in D-serine-induced nephrotoxicity.
Maekawa M; Okamura T; Kasai N; Hori Y; Summer KH; Konno R
Chem Res Toxicol; 2005 Nov; 18(11):1678-82. PubMed ID: 16300376
[TBL] [Abstract][Full Text] [Related]
78. Human D-amino acid oxidase: an update and review.
Kawazoe T; Park HK; Iwana S; Tsuge H; Fukui K
Chem Rec; 2007; 7(5):305-15. PubMed ID: 17924443
[TBL] [Abstract][Full Text] [Related]
79. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia.
Fraley ME
Expert Opin Ther Pat; 2009 Sep; 19(9):1259-75. PubMed ID: 19552508
[TBL] [Abstract][Full Text] [Related]
80. Multi-Target Approach for Drug Discovery against Schizophrenia.
Kondej M; Stępnicki P; Kaczor AA
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30309037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
